Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy
- 1 February 1996
- Vol. 18 (2), 133-139
- https://doi.org/10.1016/8756-3282(95)00448-3
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Clodronate (dichloromethylene bisphosphonate) inhibits LPS-stimulated IL-6 and TNF production by raw 264 cellsLife Sciences, 1994
- BisphosphonatesDrugs, 1991
- PamidronateDrugs, 1991
- Biological and clinical aspects of interleukin 6Immunology Today, 1990
- Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 1990
- Interleukin‐6 is the major regulator of acute phase protein synthesis in adult human hepatocytesFEBS Letters, 1989
- Interleukin‐6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritidesArthritis & Rheumatism, 1988
- Cachectin: More Than a Tumor Necrosis FactorNew England Journal of Medicine, 1987
- Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.The Journal of Experimental Medicine, 1986
- Interleukin-1 and the Pathogenesis of the Acute-Phase ResponseNew England Journal of Medicine, 1984